CYTOCHROME P450, ESTROGEN METABOLITES AND SUPEROXIDE RADICALS IN BREAST CANCER INITIATION AND PROGRESSION
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-22-1-2020-g.8582Keywords:
breast cancer, CYP 1B1, CYP 1А2, cytochrome P450, estrogens, metabolism, superoxide radicalsAbstract
Aim: to investigate levels of cytochrome P450 and its CYP 1A2, CYP 1B1 isoforms in tumor tissue (TT) and mammary adipose tissue (MAT) in patients with breast cancer (BC). Object and methods: Twenty eight patients with stage II (T3N0M0) triple-negative molecular subtype BC were involved in the study. Fifteen patients had normal body mass (BMI < 25 kg/m2), 13 — were overweight (BMI ≥ 25 kg/m2). Twenty eight samples of TT, 25 of MAT taken at a distance of 3 cm from the tumor node and 27 of MAT on the tumor border were investigated. The levels of oxidized, low-spin and high-spin cytochrome P450 and its CYP 1A2 and CYP 1B1 isoforms were examined by electron paramagnetic resonance and spectrophotometrically. Results: it was shown that the levels of cytochrome Р450 CYP 1А2 in TT and MAT bordering with the tumor tissue were lower than that of Р450 CYP 1B1 independently of patients’ BMI. In MAT taken 3 cm from the tumor nodule distribution of P450 isoforms was the opposite. Three cm apart from the tumor nodule, semiquinone levels were 0.48 ± 0.02 relative units, while in MAT bordering the tumor tissue it increased to 0.89 ± 0.05 relative units (p < 0.05). TT is characterized by the highest levels of estrogen’s free radical metabolites (2.23 ± 0.09 relative units). Quinones and theirs anion-radicals, semiquinones, are a class of toxic estrogen’s intermediates that can induce a number of adverse effects. The mechanism of quinones’ toxic effect is complex. Obviously, the direct oxidation of SH groups in mitochondrial FeS-containing proteins and the production of superoxide radicals are the main processes. Conclusion: in patients with BC, there was revealed the increase in oxidative metabolism of estrogen due to elevated levels of CYP 1B1 and decreased activity of CYP 1A2 in cells of TT and MAT bordering the tumor tissue. Unregulated growth of estrogen’s metabolite levels causes mitochondria’s metabolism reprogramming in MAT cells, increased generation of superoxide radicals, cellular hypoxia and instability of the genome functioning. Regulation of cytochrome P450 activity is a critical mechanism in estrogen homeostasis in the prevention of BC and monitoring of the tumor process.
References
DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA: A Cancer J Clin 2019; 69 (6): 438–51.
Horn J, Vatten L. Reproductive and hormonal risk factors of breast cancer: a historical perspective. Int J Women’s Health 2017; 2017 (9): 265–72.
Kirsh V, Kreiger N. Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes and Control 2002; 13 (6): 583–90.
Yue W, Wang JP, Li Y, et al. Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. Int J Cancer 2010; 127 (8): 1748–57.
Wang C, Bai F, Zhang L, et al. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression. Breast Cancer Res 2018; 20 (1): 70–4.
Park SA. Catechol estrogen 4-hydroxyestradiol is an ultimate carcinogen in breast cancer. Biomed Sci Lett 2018; 24 (3): 143–9.
Cavalieri EL, Rogan EG. Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention. Clin Transl Med 2016; 5 (1): 5–12.
Sung NJ, Park SA. Effect of natural compounds on catechol estrogen-induced carcinogenesis. Biomed Sci Lett 2019; 25 (1): 1–6.
Burlaka A, Rudiuk T, Burlaka A, Kolesnik O. 8-hydroxy-deoxyguanosine as an independent prognostic factor in patients with metastatic colorectal cancer. Arch Balk Med Union 2019; 54 (3): 445–54.
Lee AJ, Cai MX, Thomas PE, et al. Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology 2003; 144 (8): 3382–98.
Burlaka AP, Motuzyuk IM, Sydorchuk OI, Virko SV. Activity and functional characteristics of cytochrome P450 in tumors and breast adipose tissue of patients with breast cancer. Oncology 2019; 21 (4): 299–303.
Burlaka AP, Ganusevich II, Vovk AV, et al. Redox state of adipose tissue for patients with gastric cancer and its connection with the body mass index and distance from the tumor. Obesity Research & Clinical Practice 2020; 14 (1): 34–8.
Koundouros N, Poulogiannis G. Phosphoinositide 3-kinase/akt signaling and redox metabolism in cancer. Front Oncol 2018; 8: 160.
Jeong SY, Im SY. Estrogen induces CK2α activation via generation of reactive oxygen species, Biomed Sci Lett 2019; 25 (1): 23–31.
Zimarina TS, Kristensen VN, Imyanitov EN, Berstein LM. Polymorphisms of CYP1B1 and COMT in breast and endometrial cancer. Molecular Biology 2004; 38 (3): 322–8.
Hanna IH, Dawling S, Roodi N, et al. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000; 60 (13): 3440–4.
Hussain T, Alrokayan S, Upasna U, et al. Meta-analysis of genetic polymorphisms in xenobiotic metabolizing enzymes and their association with breast cancer risk. J Genetics 2018; 97 (2):, 523–37.
Androutsopoulos VP, Spyrou I, Ploumidis A, et al. Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors. PLoS ONE 2013; 8 (12): e82487.
